DUBLIN--(BUSINESS WIRE)--The "Global Cancer Immunotherapy Market Analysis & Forecast to 2023" report has been added to ResearchAndMarkets.com's offering
Within the cancer therapeutics space, which today is worth over $100 billion globally, immunotherapeutic drugs have gained worldwide acceptance.
This is because they are targeted therapeutics that have high specificity for cancer cells. Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $75 billion in 2019 alone and are forecast to surpass $115 billion in 2023.
This report describes the evolution of such a huge market in 20 chapters supported by:
- An overview of cancer immunotherapy that includes: monoclonal antibodies, ADC's, cancer vaccines and non-specific cancer immunotherapies and CAR T therapies.
- Focus on current trends in cancer immunotherapies that include: anti-PD-1 and anti-PDL1 drugs, Dendritic cell vaccines, T-cell therapies, and cancer vaccines.
- Insight into the challenges faced by drug developers, particularly about the success vs. failure ratios in developing cancer immunotherapy drugs.
- Descriptions of more than 23 cancer immunotherapeutics approved and used as targeted drugs
- Insight into the various immunotherapeutics available for specific cancer types.
- Description and data for the prevalence of cancer types that are addressed by cancer immunotherapeutics.
- Overall global cancer therapeutics market, leading market players and the best selling cancer drugs.
- Detailed account of the market for cancer immunotherapeutics by geography, indication, company, and individual drugs.
- Profiles, marketed products, and products in the pipeline of 79 companies that are located globally
- A summary table to identify the category of immunotherapy drugs offered by the 79 companies.
- A specific chapter on the CAR-T industry detailing manufacturing, regulations, and pricing
Key Topics Covered:
1.0 Executive Summary
1.1 Objectives of Report
1.2 Key Questions Answered in this Report
1.3 Data Sources and Methodology
2.0 Cancer Immunotherapy: An Overview
2.1 Human Immune System
2.2 Types of Cancer Immunotherapy
2.3 Monoclonal Antibodies (Mabs) to Treat Cancer
2.4 Types of Monoclonal Antibodies (MAbs)
2.5 Cancer Vaccines
2.6 Non-Specific Cancer Immunotherapies and Adjuvants
2.7 New Frontiers in Cancer Immunotherapy Research
2.8 Cancer Immunotherapy: Timeline of Progress
3.0 Current Status of Cancer Immunotherapy: An Overview
3.1 Programmed Death (PD-1) Inhibitors
3.2 Keytruda (Pembrolizumab, MK-3475)
3.3 Tecentriq from Roche
3.4 Pidilizumab from CureTech
3.5 An Overview of Anti-PD-1 Clinical Development
3.6 Studies with Yervoy (Ipilimumab)
3.7 Studies with Tremelimumab
3.8 KAHR-102
3.9 TIM3 Antibody
3.10 BMS-989016
3.11 ImmuTune IMP701 and ImmuFact IMP321
3.12 Dendritic Cell Therapies
3.13 Chimeric Antigen Receptor T-Cells (CAR-T) Therapies
3.14 Cancer Vaccines
3.15 Miscellaneous Immunotherapies
3.16 Most Valuable R&D Projects in Cancer Immunotherapy
4.0 Challenges in Cancer Medicine Research: An Overview
4.1 Years of Failures and Emerging Successes in Melanoma Medicine Research
4.2 A New Era for Lung Cancer Medicines
4.3 Ray of Hope for Brain Cancer Patients
5.0 Cancer Immunotherapeutic Products: An Overview
5.1 I-Labelled Tositumomab (Bexxar)
5.2 Y-Labelled Ibritumomab (Zevalin)
5.3 Alemtuzumab (Campath)
5.4 Adotrastuzumab Emtansine (Kadcyla)
5.5 Bacillus Calmette-Guerin (BCG)
5.6 Bevacizumab (Avastin)
5.7 Brentuximab Vedotin (Adcetris)
5.8 Cetuximab (Erbitux)
5.9 Cervarix
5.10 Denileukin Diftitox (Ontak)
5.11 Gardasil
5.12 Gemtuzumab (Mylotarg)
5.13 Hepatitis B Vaccine
5.14 Interferon Alfa (IFN-alfa)
5.15 Interleukin-2 (IL-2)
5.16 Ipilimumab (Yervoy)
5.17 Ofatumumab (Arzerra)
5.18 Panitumumab (Vectibix)
5.19 Pembrolizumab (Keytruda)
5.20 Rituximab (Mabthera)
5.21 Sargramostim (Leukine)
5.22 Sipuleucel-T (Provenge)
5.23 Trastuzumab (Herceptin)
6.0 Available Immunotherapies for Cancer by Disease Type: An Overview
6.1 Melanoma Skin Cancer and Immunotherapy
6.2 Breast Cancer and Immunotherapy
6.3 Immunotherapy for Prostate Cancer
6.4 Immunotherapy for Lung Cancer
6.5 Immunotherapy for Colorectal Cancer
6.6 Immunotherapies in Development for Lymphoma
6.7 Immunotherapy for Kidney Cancer
6.8 Dominance of MAbs and Vaccines in Cancer Clinical Research
6.9 Oncology Biologics Losing Patent Protection
7.0 Cancer Incidence and Mortality: An Overview
7.1 Global Economic Burden of Cancer
7.2 Global Burden of Cancer
7.3 Top Five Most Frequent Cancers, Globally
7.4 Cancer Deaths in Women
7.5 Prevalence and Mortality for Cancer Types Addressed by Immunotherapy
8.0 Global Oncology Market Analysis and Forecast to 2023
8.1 Global Oncology Market Geographical Analysis and Forecast to 2023
8.2 Top Companies in Oncology Drug Sales
8.3 FDA approved oncology drugs to 2019
8.4 Top Oncology Drug Market Forecast to 2023
8.5 Global Oncology Therapeutics Market by Cancer Type
9.0 Market for Cancer Immunotherapy
9.1 Key Drivers
9.2 Global Market for Cancer Immunotherapeutics by Geography
9.3 Global Market for Cancer Immunotherapy by Product Class
9.4 Global Market for Immunotherapy Drugs by Cancer Type
9.5 Global Market for Monoclonal Antibodies for Cancer by Type
9.6 Global Market and Forecast for Cancer Vaccines
9.7 Global Market for Non-Specific Cancer Immunotherapeutics
10.0 Company Profiles
10.1 Ablynx NV
10.2 Activartis Biotech GmbH
10.3 Advaxis Inc
10.4 Aduro BioTech Inc
10.5 Agenus Inc
10.6 AlphaVax Inc
10.7 A. Menarini Industrie Farmaceutiche Riunite Srl
10.8 Amgen Inc
10.9 Antigen Express Inc
10.10 Argos Therapeutics Inc
10.11 Bavarian Nordic A/S
10.12 Bellicum Pharmaceuticals Inc
10.13 Biogen Idec Inc
10.14 Biovest International Inc
10.15 Bristol-Myers Squibb Company
10.16 Cellectis
10.17 Cellerant Therapeutics Inc
10.18 Celldex Therapeutics
10.19 CEL-SCI Corp.
10.20 CureTech Ltd.
10.21 Delta-Vir GmbH
10.22 Dendreon Corp.
10.23 DenDrit Biotech USA
10.24 DNAtrix Inc
10.25 Eli Lilly and Co.
10.26 EMD Serono Inc
10.27 Etubics Corp.
10.28 Galena Biopharma Inc
10.29 Genentech Inc
10.30 Genmab AS
10.31 GlaxoSmithKline
10.32 Gliknik Inc
10.33 GlobeImmune Inc
10.34 Heat Biologics Inc
10.35 Immatics Biotechnologies GmbH
10.36 ImmunoCellular Therapeutics Ltd.
10.37 Immunocore Ltd.
10.38 ImmunoFrontier Inc
10.39 ImmunoGen Inc
10.40 Immunomedics Inc
10.41 Immunotope Inc
10.42 Immunovaccine Inc
10.43 Inovio Pharmaceuticals Inc
10.44 Janssen Biotech Inc
10.45 Juno Therapeutics Inc
10.46 Kite Pharma Inc
10.47 MabVax Therapeutics Holdings Inc
10.48 MedImmune LLC
10.49 Merck & Co., Inc
10.50 Merrimack Pharmaceuticals Inc
10.51 Morphotek Inc
10.52 NewLink Genetics Corp.
10.53 Northwest Biotherapeutics Inc
10.54 NovaRx Corp.
10.55 OncoPep Inc
10.56 Oncothyreon Inc
10.57 OSE Pharma SA
10.58 Oxford BioTherapeutics Ltd.
10.59 Pique Therapeutics
10.60 Polynoma LLC
10.61 Prima BioMed Ltd.
10.62 Progenics Pharmaceuticals Inc
10.63 Regen Biopharma Inc
10.64 Roche Holdings Inc
10.65 Seattle Genetics Inc
10.66 Sorrento Therapeutics Inc
10.67 Spectrum Pharmaceuticals Inc
10.68 Synthon Pharmaceuticals Inc
10.69 TapImmune Inc
10.70 ThioLogics Ltd.
10.71 Transgene SA
10.72 TVAX Biomedical Inc
10.73 Vaccinogen Inc
10.74 Viventia Biotechnologies Inc
10.75 Wilex AG
10.76 Ziopharm Oncology Inc
11.0 Cancer Immunotherapy Market Participants by Product Segment
12.0 CAR T Therapy
12.1 Challenges Relating to Chimeric Antigen Receptor T Cells in Immunotherapy
13.0 Regulations Pertaining to Immunotherapy Regulation in the USA
13.1 Center for Biologics Evaluation and Research (CBER)
14.0 Regulations for Immunotherapy in Japan
14.1 PMDA and Immunotherapy
15.0 European Regulation and Immunotherapeutics
15.1 Introduction
15.2 Challenges for Immunotherapy in EMEA
15.3 Challenges Relating to Biomarkers in Immunotherapy
15.4 Challenges Relating to Chimeric Antigen Receptor T Cells in Immunotherapy
15.5 Estimating Optimal Cut-Off Parameters
15.6 EU-Approved Immunotherapies in Melanoma
15.7 Key Contacts Within EMA for Immunotherapeutics
16.0 Manufacturing of Immunotherapies
16.1 Introduction
16.2 Generation of CAR-Modified T Cells
16.3 Manufacturing Devices and Instruments Required for Immunotherapy Production
16.4 Good Manufacturing Procedure (GMP) for Immunotherapy
16.5 Case Study Production of Lentivirus Induced Dendritic Cells under GMP Conditions
16.6 Quality Control
16.7 Regulatory Affairs
16.8 Key Challenges in Manufacturing
17.0 Supply Chain & Logistics
17.1 Introduction
17.2 Case Study: Juno Therapeutics
18.0 Pricing & Cost Analysis
18.1 Introduction
18.2 CAR T Therapy Market Evaluation
19.0 Current Deals Within the CAR T Market
20.0 CAR T Therapy Company Case Studies
20.1 Juno Therapeutics
20.2 Kite Pharma
20.3 Cellectis
For more information about this report visit https://www.researchandmarkets.com/r/4oiy3p
